{"Clinical Trial ID": "NCT00876395", "Intervention": ["INTERVENTION 1:", "Everolimus + Paclitaxel + Trastuzumab", "Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 per week on days 1, 8, 15 and trastuzumab 2mg/kg per week on days 1, 8, 15, 22", "INTERVENTION 2:", "Placebo + Paclitaxel + Trastuzumab", "Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 per week on days 1, 8, 15 and trastuzumab 2mg/kg per week on days 1, 8, 15, 22"], "Eligibility": ["Incorporation criteria:", "Adult women (18 years of age).", "Invasive breast carcinoma confirmed histologically or cytologically with local recurrence or radiological evidence of metastatic disease.", "There must be at least one injury that can be measured accurately or bone damage in the absence of measurable disease.", "HER2+ patients by local laboratory tests (IHC 3+ colouring or positive in situ hybridization).", "Prior treatment with trastuzumab and/or chemotherapy (including taxanes) with neoadjuvant or adjuvant is allowed, but should be discontinued more than 12 months prior to randomisation.", "A prior treatment of breast cancer with endocrine (adjuvant or metastatic) treatment is permitted but should be discontinued at randomisation. Patients treated with bisphosphonates at entry or who begin bisphosphonates during the study may continue this treatment during protocol treatment.", "\u2022 Documentation of the negative pregnancy test.", "Functions of the organ at the time of inclusion.", "- Exclusion criteria:", "Previous mTOR inhibitors for the treatment of cancer.", "Other anticancer therapy for locally advanced or metastatic breast cancer, with the exception of prior hormonal treatment.", "* Patients with only unmeasurable lesions other than bone metastases (e.g. pleural effusion, ascites, etc.).", "In the 4 weeks prior to randomisation, 25% of the bone marrow radiation therapy", "History of central nervous system metastases.", "\u2022 Impairment of gastrointestinal function (GI) or gastrointestinal disease or active ulceration of the upper gastrointestinal tract.", "A serious peripheral neuropathy.", "A heart disease or dysfunction.", "- Uncontrolled hypertension.", "HIV.", "Pregnant,"], "Results": ["Performance measures:", "Based on the local radiology test - complete population", "SSP is defined as the period from the date of randomization to the date of the first documented tumour progression or death of any cause, whichever occurs first.", "Time limit: date of randomization until the date of the first documented tumour progression or death of any cause, whichever occurs first, reported between the day of the first randomised patient up to approximately 56 months", "Results 1:", "Title of the arm/group: Everolimus + Paclitaxel + Trastuzumab", "Description of the arm/group: Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 per week on days 1, 8, 15 and trastuzumab 2mg/kg per week on days 1, 8, 15, 22", "Total number of participants analysed: 480", "Median (95% confidence interval)", "Unit of measure: month 14.95 (14.55 to 17.91)", "Results 2:", "Title of arm/group: Placebo + Paclitaxel + Trastuzumab", "Description of the arm/group: Placebo of everolimus 10 mg per day in combination with paclitaxel 80mg/m2 per week on days 1, 8, 15 and trastuzumab 2mg/kg per week on days 1, 8, 15, 22", "Total number of participants analysed: 239", "Median (95% confidence interval)", "Unit of measure: month 14.49 (12.29 to 17.08)"], "Adverse Events": ["Undesirable Events 1:", "Total: 173/472 (36.65 per cent)", "Anemia 6/472 (1.27 per cent)", "- Febrile neutropenia 4/472 (0.85%)", "Iron deficiency anaemia 1/472 (0.21%)", "Leukopenia 2/472 (0.42%)", "Neutropenia 2/472 (0.42%)", "Thrombocytopenia 4/472 (0.85%)", "Acute myocardial infarction 1/472 (0.21%)", "Incompetence of aortic valve 0/472 (0.00 %)", "Atrial fibrillation 2/472 (0.42%)", "Cardiac arrest 1/472 (0.21%)", "Adverse Events 2:", "Total: 40/238 (16.81 per cent)", "Anemia 0/238 (0.00 %)", "Febrile neutropenia 1/238 (0.42%)", "Iron deficiency anaemia 0/238 (0.00 %)", "- Leucopenia 0/238 (0.00 %)", "Neutropenia 2/238 (0.84%)", "Thrombocytopenia 0/238 (0.00 %)", "- Acute myocardial infarction 0/238 (0.00 %)", "Incompetence of aortic valve 1/238 (0.42%)", "Atrial fibrillation 0/238 (0.00 %)", "Cardiac arrest 0/238 (0.00 %)"]}